ALMR Q3'26 Earnings: revenue estimate is 30.22M USD

What happened

Alamar Biosciences will report third-quarter 2026 results on November 3 after the market closes, at 4:00 PM ET. The revenue estimate is 30.22 million USD, and the earnings per share estimate is (0.20) USD, meaning a expected loss per share.

Confirmed

Global impact / market context

The revenue estimate of 30.22 million USD is higher than prior quarterly estimates shown, suggesting analysts expect sales growth. The negative earnings per share estimate means the company is expected to report a loss, so investors will weigh revenue growth against continuing costs.

Analyst inference

Alamar Biosciences is a relatively new public company, and its reported results have previously beaten estimates. That history may shape investor positioning ahead of the release, with attention on whether revenue meets the 30.22 million USD estimate.

Analyst inference

What to watch

1. Watch whether reported revenue matches the 30.22 million USD estimate and whether earnings per share matches the (0.20) USD estimate, since these are the published consensus figures. Confirmed
2. Compare actual revenue with the 30.22 million USD estimate to judge demand for Alamar's products, and check whether earnings per share shows a smaller loss than the (0.20) USD estimate. Proposed
3. Track whether the company's reported results continue its past pattern of beating estimates, because a miss could change how investors value the stock after the November 3 release. Analyst inference

Evidence

• Original source link unavailable